Harmony Biosciences Management, Inc.

Clinical trials sponsored by Harmony Biosciences Management, Inc., explained in plain language.

Harmony Biosciences Management, Inc. HRMY NASDAQ

Develops treatments for rare neurological diseases, including narcolepsy.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New drug aims to tackle sleepiness in rare genetic disorder Results expected Apr 2027 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 4 Not yet finished but already full! 1 Completed 7

New drug pitolisant tested for safety in rare genetic disorder

Disease control By invitation only

This phase 3 trial is testing the safety of pitolisant in 150 people with Prader-Willi syndrome who have already taken the drug in a previous study. Participants will receive pitolisant tablets and be monitored for side effects. The goal is to see if pitolisant is safe for long-t…

Phase 3 • Sponsor: Harmony Biosciences Management, Inc. • Aim: Disease control

Last updated Jun 27, 2026 11:02 UTC

Harmony Biosciences Management, Inc.

Upcoming readouts

New drug pitolisant tested for safety in rare genetic disorder